Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan最新文献

{"title":"Application of promoting blood circulation and resolving blood stasis in intracerebral hemorrhage: a traditional method gradually being reconsidered.","authors":"Zhang Dingshan, Chen Li, Maryam Mazhar, Xue Jinyi, Liu Ping, Liu Mengnan","doi":"10.19852/j.cnki.jtcm.2025.02.017","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.017","url":null,"abstract":"<p><p>Intracerebral hemorrhage (ICH) is a significant and growing threat to human health, with increasing incidence. Promoting blood circulation and removing blood stasis therapy (PBCRBS), a Traditional Chinese Medicine therapy, can be an adjuvant therapy to benefit patients with ICH by improving clinical efficacy. However, in theory, using PBCRBS to treat ICH carries the risk of hematoma enlargement and rebleeding, which has led to controversy over its application in ICH treatment. To demonstrate the effectiveness and safety of PBCRBS in treating ICH, this review first analyzes the pathological and physiological basis of ICH and secondly, the cascade of response after ICH and the involvement of cytokines and signaling pathways in this process. Finally, experimental and clinical studies on the treatment of ICH with PBCRBS over the past decade were retrieved from the PubMed and China National Knowledge Infrastructure databases, and the content of these studies was used to summarize commonly used herbs with PBCRBS effects and their mechanisms of action. Through analysis, hypertension has been identified as the most common cause of ICH. Heme, interleukin, reactive oxygen species, coagulation promoting particles and other induced mass effects, inflammation, oxidative stress, and coagulation cascade reactions lead to brain damage following ICH. This review includes 56 experimental studies and 83 clinical studies summarizing 28 commonly used herbs, demonstrating the positive impact of PBCRBS as an adjuvant therapy for ICH. In summary, PBCRBS appears effective and safe for treating ICH.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"458-472"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypolipidemic effect and mechanism of Hedan tablet based on network pharmacology.","authors":"H U Huiming, Weng Jiajun, Tang Fangrui, Wang Yaqi, Fan Shengxian, Wang Xuecheng, Cui Can, Shao Feng, Zhu Yanchen","doi":"10.19852/j.cnki.jtcm.2025.02.015","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.015","url":null,"abstract":"<p><strong>Objective: </strong>To examine Hedan tablet (HDT, )'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet (HFD), as well as its regulatory effects and primary active constituents.</p><p><strong>Methods: </strong>By using ultra-performance liquid chromatography (UPLC)-quadrupole-time-of-flight (QTOF)-tandem mass spectrometry (MS/MS), the components of HDT that can enter the circulatory system were found, aiming to investigate its active constituents with pharmacological effects. Based on network pharmacology approaches, the relevant HDT targets in the therapy of hyperlipidemia were anticipated. The possible mechanism of HDT for hyperlipidemia treatment was verified by <i>in-vivo</i> experiments, and the main active components of HDT for hyperlipidemia treatment were analyzed <i>via in-vitro</i> experiments.</p><p><strong>Results: </strong>UPLC-QTOF-MS/MS identified 30 components of HDT entering the circulatory system, primarily consisting of flavonoids, diterpenoids and alkaloids. The results of a network pharmacology study revealed that 30 active components mostly target 74 genes associated with hyperlipidemia. The primary active ingredients may include quercetin, kaempferol, and epicatechin, and the main gene targets may be tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin 1 beta (IL-1β), etc. The results of animal experiments demonstrated that HDT can significantly regulate the blood lipid level in rats with HFD, improve the degree of inflammatory infiltration in rat liver cells, lower TNF-α, C-reactive protein (CRP), IL-6, matrix metalloproteinase 9 (MMP9) and malondialdehyde (MDA) levels while raising total superoxide dismutase (T-SOD) level. Meanwhile, HDT can considerably lower the expression of sterol regulatory element-binding transcription factor 2 (SREBF2), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and MMP9 while significantly increasing the expression of peroxisome proliferator-activated receptor alpha (PPAR-α) and PPAR-γ. <i>In vitro</i> study confirmed that quercetin and kaempferol could reduce the levels of IL-6, IL1B, MMP9 and HMGCR in the high-fat model of hepatoma G2 cells.</p><p><strong>Conclusions: </strong>The mechanism by which HDT treats hyperlipidemia involves modification of the lipid metabolism targets such as downregulating SREBF2, HMGCR and MMP9, and upregulating PPAR-α and PPAR-γ, as well as anti-inflammatory and antioxidant actions. This study provides a pharmacological and biological rationale for the use of HDT in clinical hyperlipidemia management.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"408-421"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jinxin oral liquid reduced lung inflammation in influenza A virus infected mice through inhibiting NOD-like receptor protein 3 pathway.","authors":"L I Tao, Wang Xianzheng, Xiong Yingcai, Dai Qigang, Wang Shouchuan, J I Jianjian","doi":"10.19852/j.cnki.jtcm.2025.02.022","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.022","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the therapeutic effects of Jinxin oral liquid (, JX) on influenza A virus（H1N1）influenza virus infected mice.</p><p><strong>Methods: </strong>We established a model of by intranasally infecting the mice with H1N1 virus. The mice were then orally administered JX or ribavirin to evaluate their therapeutic effects in vivo. We conducted histologic and immunohistochemical analyses, enzyme linked immunosorbent assay or quantitative real-time polymerase chain reaction to assess lung damage and the expression of inflammatory cytokines. Western blot (WB) experiments was conducted to measure the activation of NOD-like receptor protein 3 (NLRP3) pathway. Flow cytometry was employed to quantify the populations of alveolar macrophages (AMs). To block the NLRP3 pathway, mice were treated with MCC950. For AMs depletion, mice were intranasally administered a single dose of clodronate liposome.</p><p><strong>Results: </strong>Administration of JX demonstrated a protective effect against H1N1-induced lung pathology by reducing lung injury, suppressing lung inflammation, and decreasing viral titer. JX significantly inhibited the production of pro-inflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor-ɑ, in H1N1-infected mice. JX inhibits the activation of NOD-like receptor protein 3 (NLRP3)/apoptosis-associated speck-like protein containing a caspase recruitment domain/ caspase 1 pathway in the lungs and AMs of H1N1-infected mice. The inhibitory effect of JX on IL-1β secretion was mediated by blocking the NLRP3 pathway activation in AMs.</p><p><strong>Conclusions: </strong>These findings suggest that JX holds promise as a potential therapeutic agent for suppressing the aggressive pro-inflammatory response induced by H1N1 infection. Further research and development are warranted to explore the full potential of JX in the prevention and treatment of H1N1 infection.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"281-290"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology approach to unveiling the mechanism of berberine in the amelioration of morphine tolerance.","authors":"Han Shuai, Du Zhikang, Wang Zirui, Huang Tianfeng, G E Yali, Shi Jianwen, Gao Ju","doi":"10.19852/j.cnki.jtcm.2025.02.012","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.012","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the mechanism underlying the effect of the Huanglian decoction (, HLD) on morphine tolerance (MT), using network pharmacology, and to verify these mechanisms <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>Methods: </strong>Available biological data on each drug in the HLD were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. The target proteins of MT were retrieved from the GeneCards, PharmGkb, Therapeutic Target Database, DrugBank, and Online Mendelian Inheritance in Man databases. Information regarding MT and the drug targets was compared to obtain overlapping elements. This information was imported into the Search Tool for the Retrieval of Interacting Genes/Proteins platform to obtain a protein-protein interaction network diagram. Then, a \"component-target\" network diagram was constructed using screened drug components and target information, <i>via</i>Cytoscape (Institute for Systems Biology, Seattle, WA, USA). The database for annotation, visualization, and integrated discovery was used for Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathways analyses. Pathway information predicted by network pharmacology was verified using animal studies and cell experiments.</p><p><strong>Results: </strong>Network pharmacology analysis identified 22 active compounds of HLD and revealed that HLD partially ameliorated MT by modulating inflammatory, apoptosis, and nuclear factor kappa B (NF-κB) signaling pathways. Berberine (BBR), one of the main components of HLD, inhibited the development of MT in mice. BBR reduced cell viability while increasing B-cell lymphoma 2 (Bcl-2) protein expression and decreasing CD86, NF-κB, Bax, and Caspase-3 protein expression in brain vascular 2 (BV2) mcroglia cells treated with morphine. Additionally, BBR contributed to a reduction in pro-inflammatory cytokine release and apoptotic cell number.</p><p><strong>Conclusions: </strong>BBR, a key component of HLD, effectively suppressed microglial activation and neuro-inflammation by regulating the NF-κB and apoptosis signaling pathways, thereby delaying MT. This study offers a novel approach to enhance the clinical analgesic efficacy of morphine.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"376-384"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of electro-acupuncture at \"Weizhong\" (BL40) on macrophage polarization in rats with injured lumbar multifidus.","authors":"Tian Yuan, B U He, Wang Tieshan, Yang Dongliang, Zhang Wei, Liu Tong, Zhang Li, Huo Zejun","doi":"10.19852/j.cnki.jtcm.20220419.001","DOIUrl":"10.19852/j.cnki.jtcm.20220419.001","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the anti-inflammatory effect of electroacupuncture in rats with bupivacaine-induced lumbar multifidus injury and its underlying regulatory mechanism on macrophage polarization.</p><p><strong>Methods: </strong>A total of seventy-two Sprague-Dawley male rats were randomly divided into control, model, and electroacupuncture groups. Forty-eight rats categorized in model groups were injected 0.5% bupivacaine (BPVC) into the lumbar multifidus at the L4-L5 segment. Rats in the electroacupuncture groups received the intervention for 1, 2, 3 and 5 d, respectively. The degree of macrophage infiltration and change of M1/M2 polarization were observed based on hematoxylin and eosin staining, immunohistochemistry and immunofluorescence to evaluate the anti-inflammatory effect of electroacupuncture. Meanwhile, exosomal miRNA-sequencing and bioinformatics analysis predicted the pathways and biological processes related to inflammatory response and macrophage polarization regulated by electroacupuncture intervention.</p><p><strong>Results: </strong>BPVC injection induced the infiltration of local macrophages at the L4-L5 segment of lumbar multifidus. Comparison of mean IOD values with 2 d and 5 d post injury revealed the highest expression of CD68+ macrophages on day 3 post injury by immunohistochemistry. (<i>P</i> < 0.001, <i>P</i> < 0.001, respectively). Compared with the model group, the cell counts of iNOs+ CD68+ M1-macrophages were lower in the electroacupuncture group, while the positive percent of CD163+ CD206+ M2-macrophages was higher in the electroacupuncture group, on day 3 after BPVC injection (<i>P</i> < 0.001, <i>P</i> < 0.001, respectively). Moreover, the results of sequencing and bioinformatic analysis suggested that exosomal miRNAs were involved in the EA regulating macrophage polarization.</p><p><strong>Conclusions: </strong>Electroacupuncture can promote macrophage polarization to reduce inflammation following lumbar multifidus muscular injury.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"335-347"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of Huayu Qutan recipe anti-atherosclerosis mediates lipophagymammalian target of rapamycin complex 1/ transcription factor EB signaling pathway in ApoE-/-mice.","authors":"L I Yue, Pan Jiaxiang, Yang Guanlin, Y U Jiajia, W U Xize, Min Dongyu, Cheng Meijia, Y U Dongdong, Nan Minghua, Gao Xiaoyu, Pang Linlin, Gong Lihong, Jia Lianqun","doi":"10.19852/j.cnki.jtcm.2025.02.016","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.016","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of Huayu Qutan recipe (, HYQT) on the atherosclerosis (AS) model of ApoE-/- mice with a high-fat diet and to illustrate the underlying mechanisms from modern patho-physiological conceptualizations.</p><p><strong>Methods: </strong>High performance liquid chromatography of quadrupole time of flight-tandem mass spectrometry (HPLC-Q-TOF-MS/MS) analysis was used to identify the active compounds in the recipe. The mice were randomly allocated into 7 groups: control (CTRL) group, normal diet (ND) group, high-fat diet (HFD) group, HYQT groups (low dose, medium dose, and high dose), and simvastatin (SIM) group. Deferent doses of HYQT were gavaged twice a day, and then the protective effect of HYQT on plaque formation in ApoE-/- mice with a high-fat diet was verified <i>via</i>hematoxylin-eosin (HE) staining and oil red o (ORO) staining. We observed the co-localization in aortic macrophages and lipid droplets (LDs) by CD68 and the Bodipy fluorescence probe. Light chain 3 phosphoprotein class Ⅱ/light chain 3 phosphoprotein class Ⅰ (LC3Ⅱ/LC3Ⅰ) was examined by western blotting, and sequestosome 1 (SQSTM1/p62), Beclin1, Lamp1, mammalian target of rapamycin (mTOR), phosphorylated mammalian target of rapamycin (p-mTOR), and ATP-binding cassette transporter A1 (ABCA1) were examined by real-time polymerase chain reaction (RT-PCR) and Western blotting. Transcription factor EB (TFEB) nuclear translocation was determined by immunofluorescence analysis.</p><p><strong>Results: </strong>Five active compounds were identified using HPLC-Q-TOF-MS/MS analysis: ferulic acid, chlorogenic acid, calycosin, formononetin, and 8,2'-dihydroxy-7,4'-dimethoxy-isoflavane. The effect of HYQT on atherosclerotic plaque formation in ApoE-/- mice was investigated. These findings showed that HYQT decreased the co-localization of CD68 and Bodipy and increased the co-localization of CD68 and LC3B. Medium and high doses of HYQT increased autophagosome formation and promoted the maturation of LC3Ⅱ/LC3Ⅰ. Additionally, HYQT decreased the expression of SQSTM1/p62. Medium and high doses of HYQT also increased the expression of Beclin1 and Lamp1. RT-PCR and Western blot results suggested that HYQT enhanced the expression of ABCA1 mRNA and protein and regulated the mTORC1/TFEB signaling pathway.</p><p><strong>Conclusion: </strong>The results indicate that HYQT is an effective traditional Chinese herbal remedy for the treatment of AS. HYQT mitigates macrophage-derived foam cell formation by activating autophagy in atherosclerosis. The mTOR/TFEB signaling pathway and ABCA1 are therapeutic targets of HYQT for the treatment of AS.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"291-302"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of Qigu capsule as a treatment for sarcopenia based on network pharmacology and experimental validation.","authors":"Shi Jinyu, Pan Fuwei, G E Haiya, Yang Zongrui, Zhan Hongsheng","doi":"10.19852/j.cnki.jtcm.2025.02.001","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.001","url":null,"abstract":"<p><strong>Objective: </strong>To explore the potential molecular mechanism of Qigu capsule (，QGC) in the treatment of sarcopenia through network pharmacology and to verify it experimentally.</p><p><strong>Methods: </strong>The active compounds of QGC and common targets between QGC and sarcopenia were screened from databases. Then the herbs-compounds-targets network, and protein-protein interaction (PPI) network was constructed. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed by R software. Next, we used a dexamethasone-induced sarcopenia mouse model to evaluate the anti-sarcopenic mechanism of QGC.</p><p><strong>Results: </strong>A total of 57 common targets of QGC and sarcopenia were obtained. Based on the enrichment analysis of GO and KEGG, we took the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway as a key target to explore the mechanism of QGC on sarcopenia. Animal experiments showed that QGC could increase muscle strength and inhibit muscle fiber atrophy. In the model group, the expression of muscle ring finger-1 and Atrogin-1 were increased, while myosin heavy chain was decreased, QGC treatment reversed these changes. Moreover, compared with the model group, the expressions of p-PI3K, p-Akt, p-mammalian target of rapamycin and p-Forkhead box O3 in the QGC group were all upregulated.</p><p><strong>Conclusion: </strong>QGC exerts an anti-sarcopenic effect by activating PI3K/Akt signaling pathway to regulate skeletal muscle protein metabolism.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"399-407"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Jianpi formulas in reducing the recurrence of colorectal adenoma after polypectomy: a systematic review and Meta-analysis.","authors":"Xiao Jing, Song Danlei, Liang Caiming, H E Yinuo, Zheng Weifang, W U Xiaqiu","doi":"10.19852/j.cnki.jtcm.2025.02.008","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.008","url":null,"abstract":"<p><strong>Objectives: </strong>To systematically review the efficacy and safety of Jianpi formulas in reducing the recurrence of colorectal adenoma (CRA) after poly-pectomy.</p><p><strong>Methods: </strong>Randomized controlled trials (RCTs) investigating Jianpi formulas for CRA post-polypectomy were systematically retrieved from eight electronic databases. The quality of the methodology was assessed using the Cochrane collaboration tool. The Grades of Recommendations Assessment Development and Evaluation (GRADE) approach was employed for evidence assessment. Statistical analyses were conducted using Statistics and Data Analysis (STATA) 17 (StataCorp (College Station, TX, USA) and Review Manager (RevMan) 5.4 (The Cochrane Collaboration (London, UK).</p><p><strong>Results: </strong>The Meta-analysis, encompassing 18 RCTs with 1838 patients, revealed that Jianpi formulas significantly outperformed postoperative routine treatment. It demonstrated a reduction in the half-year recurrence rate [relative risk (<i>RR</i>) = 0.41, 95% confidence interval (<i>CI</i>) = 0.33-0.49, <i>Z</i> = 9.08, <i>P <</i> 0.000 01], the one-year recurrence rate [<i>RR</i> = 0.58, 95% <i>CI</i>= 0.49-0.69, <i>Z</i>= 6.12, <i>P <</i> 0.000 01], and an enhancement in the clinical effective rate [<i>RR</i> = 1.27, 95% <i>CI</i> = 1.19-1.36, <i>Z</i>= 7.06, <i>P <</i> 0.000 01]. The half-year recurrence rate and the clinical effective rate were medium-quality evidence. The one-year recurrence rate was low-quality evidence. Additionally, Jianpi formulas appear to be safe and do not increase adverse reactions compared to postoperative routine treatment alone.</p><p><strong>Conclusion: </strong>Jianpi formulas exhibit efficacy in reducing postoperative half-year and one-year recurrence rates while improving the clinical effective rate after polypectomy for CRA.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"225-233"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update evidence of effectiveness on pain relieving of cupping therapy: a systematic review and Meta-analysis of randomized controlled trials.","authors":"Wang Yiying, Dong Shuai, L I Bo, Han Mei, Cao Huijuan","doi":"10.19852/j.cnki.jtcm.2025.02.002","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.002","url":null,"abstract":"<p><strong>Objective: </strong>To update the current best evidence on the effectiveness and safety of cupping therapy in pain management.</p><p><strong>Methods: </strong>The protocol of this systematic review was registered at PROSPERO (CRD42021261308). An updated literature searching in 7 databases was conducted from January 2014 to January 2023. Two authors extracted data and assessed the risk of bias independently. Statistical analysis was performed using RevMan 5.4.1 software (Cochrane Collaboration, London, UK). Meta-analysis with a random effect model was conducted when there was no serious statistical heterogeneity among trials (<i>I</i>2≤75%). Grading of Recommendations Assessment, Development, and Evaluation was also conducted to assess the quality of evidence.</p><p><strong>Results: </strong>Seventy-two trials with 5720 participants were included. All included trials were assessed as having high risk of bias. The majority of the included trials reported the benefit of cupping plus other therapy or cupping alone on improving cure rate (average risk ratio more than 1.15) and reducing visual analogue scale [average mean difference (<i>MD</i>) reduction 0.16 to 7.0 cm], improving quality of life, quality of sleep or other symptoms related to pain condition. And there was low/very low quality evidence that the incidence of adverse events in the cupping groups were lower than that in the control groups. Although the heterogeneity between studies and the methodological quality of the study itself lead to the low evidence strength of the current conclusions, the results of this study are a valuable supplement to the founding of previous review.</p><p><strong>Conclusion: </strong>Cupping therapy alone or combined with other therapy was considered benefit in relieving pain, improving the quality of life, and increasing the cure rate of patients with pain conditions, though supported by the low quality of evidence. According to the limited evidence, cupping therapy seems to have less harm than drugs when treating pain conditions.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"234-253"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy of Angong Jiangya pill for grade 2 hypertension with liver-fire hyperactivity syndrome: a randomized, double-blind, placebo-controlled, multicenter trial.","authors":"Lai Xiaolei, Shang Juju, Liu Hongxu, H U Jing, L I Xiang, Zhang Zhenmin, Xing Wenlong","doi":"10.19852/j.cnki.jtcm.2025.02.010","DOIUrl":"10.19852/j.cnki.jtcm.2025.02.010","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of Angong Jiangya pill (AGJY, ) in the treatment of grade 2 hypertension with liver-fire hyperactivity syndrome.</p><p><strong>Methods: </strong>This multicenter, randomized, double-blind, placebo-controlled trial was conducted in eight medical institutions. Eligible patients with grade 2 hypertension were randomly allocated to receive AGJY or a placebo for 12 weeks. The primary outcome was the change in blood pressure (BP). The secondary outcomes were BP compliance rate, Traditional Chinese Medicine (TCM) symptoms, and Duchenne Hypertension Quality of Life Scale score.</p><p><strong>Results: </strong>Data were analyzed for 117 participants in the AGJY group and 118 participants in the placebo group. After 12 weeks of treatment, AGJY compared with placebo resulted in a higher and significant reduction in systolic/diastolic BP (－15.58 ± 10.16/－9.72 ± 7.41 <i>vs</i> －8.13 ± 8.28/－4.86 ± 5.68 mm Hg, <i>P <</i> 0.0001, < 0.0001, respectively). BP compliance rate (31.86% <i>vs</i> 19.13%, <i>P</i>= 0.027) was significantly higher in the AGJY group than in the placebo group. The AGJY group showed a significant reduction in TCM symptom score compared with the placebo group (10.82 ± 2.03 <i>vs</i> 7.83 ± 1.24, <i>P</i>< 0.0001). Single TCM syndrome clinical control rates of the primary symptoms (dizziness, headache, and irritability) were superior in the AGJY group (71.95%, 94.62%, 72.53%, respectively) compared with the placebo group (48.39%, 68.00%, 30.52%, respectively). Scores on the Duchenne Hypertension Quality of Life Scale showed a significant increase in the AGJY group compared with the placebo group (30.65 ± 21.06 <i>vs</i> 9.96 ± 10.72, <i>P</i>= 0.000). No serious adverse events occurred.</p><p><strong>Conclusion: </strong>AGJY demonstrated efficacy in lowering BP, increasing the rate of BP compliance, and improving TCM symptoms and quality of life in patients with grade 2 hypertension liver-fire hyperactivity syndrome. However, further in-depth studies are required to determine the mechanism of TCM in treating hypertension.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 2","pages":"422-429"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}